¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Large-Conductance Calcium-Activated Potassium Channel beta Subunits"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® potassium ÇÑ±Û Ä®·ý
¼³¸í   
  ¿ø¼Ò ±âÈ£ 19¹øÀ̰í K·Î Ç¥½ÃÇϴ ȭÇÐÀû ¿ø¼Ò·Î ¼¼Æ÷ ³»¾×ÀÇ °¡Àå ¸¹Àº ¾çÀÌ¿ÂÀ̱⵵ ÇÏ´Ù.
¿µ¹® beta human chorionic gonadotropin ÇÑ±Û º£Å¸ »ç¶÷À¶¸ð¼º »ý½Ä»ùÀÚ±ØÈ£¸£¸ó
¼³¸í   
  Å¹ݼ¼Æ÷¿¡¼­ ¸¸µé¾îÁö´Â È£¸£¸ó. ±â´ÉÀº ÀÓ½ÅÀÇ Ãʱ⿡ È²Ã¼(¿ø·¡ ³­ÀÚ¸¦ ½Î°í ÀÖ´ø ¼¼Æ÷µéÀÌ ¹è¶õÀÌ ÀϾ¼­ ³­ÀÚ°¡ ºüÁ®³ª°£ ÈÄ ÁÖ¸Ó´Ï ¸ð¾çÀ» ÀÌ·é °Í. ÀÓ½ÅÃʱ⿡ ÀÓ½ÅÀÇ À¯Áö¿¡ ÇÊ¿äÇѠȣ¸£¸óÀ» »ý¼ºÇÑ´Ù)ÀÇ À¯Áö¿¡ ±â¿©Çϰí, Å¾ÆÀÇ °íȯÁ¶Á÷¿¡¼­ ³²¼ºÈ£¸£¸óÀÌ ºÐºñµÇ´Â °ÍÀ» ÃËÁø½ÃŲ´Ù. ¶Ç À̰ÍÀº ÀÓ½ÅÃʱâÀÇ ÀÓ»êºÎÀÇ ¼Òº¯¿¡¼­ ¸¹Àº ¾çÀÌ °ËÃâµÇ¹Ç·Î À̰ÍÀ» ÀÌ¿ëÇØ¼­ ÀÓ½ÅÀÇ ¿©ºÎ¸¦ ¼Õ½±°Ô Á¶»çÇÒ ¼ö°¡ ÀÖ´Ù.
¿µ¹® beta ray ÇÑ±Û º£Å¸¼±
¼³¸í   
  ¹æ»ç¼º ¿øÀÚÇÙÀÌ ¥âºØ±«ÇÔ¿¡ µû¶ó ¹æÃâµÇ´Â ¹æ»ç¼±. ¿øÀÚ¿¡ Á¤»óº¸´Ù ¸¹°Å³ª ÀûÀº Áß¼ºÀÚ³ª ¾çÀÚ¸¦ °¡Áö°í Àִ °æ¿ì¿¡´Â ¿øÀÚ°¡ ¾ÈÁ¤µÇ±â À§ÇÏ¿© ºØ±«°¡ ¼¼°¡Áö ¹æ¹ýÀ¸·Î »ý±ä´Ù. ÀÌÁß Áß¼ºÀÚ°¡ ÇϳªÀÇ ÀüÀÚ¸¦ ³»°í ¾ç¼ºÀÚ°¡ µÇ´Â º¯È­¸¦ °ÅÄ¡¸é¼­ ³ª¿À´Â ÀüÀÚ¼±ÀÌ´Ù. ±× ½Çü´Â °í¼ÓÀÇ ÀüÀÚ ¶Ç´Â ¾çÀüÀÚÀ̸ç ÃÖ´ë ¿¡³ÊÁö´Â 105-107eV. Åõ°ú·Â ¹× ÀÌ¿ÂÈ­ ÀÛ¿ëÀº ¥á¼±°ú ¥ã¼±ÀÇ Áß°£ Á¤µµÀÌ´Ù.
¿µ¹® beta-blocker ÇÑ±Û º£Å¸Â÷´ÜÁ¦
¼³¸í   
  º£Å¸-¼ö¿ëü(1°ú 2¿¡ °ü°è¾øÀÌ)ÀÇ ±â´ÉÀ» ¾ïÁ¦½Ã۴ ¾à¹°·Î ÀÌ ¼ö¿ëü°¡ ¸Å°³ÇÏ¿© »ý±â´Â ½ÅüÀÇ º¯È­¸¦ ¾ïÁ¦ÇÑ´Ù. PropranololÀÌ ÁÁÀº ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium
    Ä®·ý
  • potassium chloride
    ¿°È­Ä®·ý
  • potassium sparing diuretic
    Ä®·ýº¸ÀüÀÌ´¢Á¦
  • potassium-losing nephritis
    Ä®·ý»ó½ÇÄáÆÏ¿°, Ä®·ý»ó½Ç½ÅÀå¿°
  • sodium-potassium pump
    ³ªÆ®·ýÄ®·ýÆßÇÁ
  • collateral channel
    °çÅë·Î
  • collector channel
    Áý°á°ü, Áý°á·Î
  • cation channel
    ¾çÀÌ¿ÂÅë·Î
  • calcium-channel blocker
    Ä®½·Åë·ÎÂ÷´ÜÁ¦
  • channel
    Åë·Î
  • channel block
    Åë·ÎÂ÷´Ü
  • fast channel
    ±Þ¼ÓÅë·Î
  • gated channel
    °ü¹®Åë·Î
  • ion channel disorder
    ÀÌ¿ÂÅë·ÎÁúȯ
  • sodium channel
    ³ªÆ®·ýÅë·Î
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • channel
    Åë·Î
  • potassium chloride
    ¿°È­Ä®·ý
  • sodium channel
    ³ªÆ®·ýÅë·Î
  • potassium
    Ä®·ý
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta hemolysis
    º£Å¸¿ëÇ÷
  • beta ray
    º£Å¸¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium chloride
    ¿°È­Ä®·ý
  • potassium sparing diuretic
    Ä®·ýº¸ÀüÀÌ´¢Á¦
  • potassium-losing nephritis
    Ä®·ý»ó½ÇÄáÆÏ¿°
  • potassium
    Ä®·ý
  • sodium-potassium pump
    ³ªÆ®·ýÄ®·ýÆßÇÁ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâ±â
  • beta error
    Á¦ÀÌÁ¾¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • channel block
    Åë·ÎÂ÷´Ü
  • channel
    Åë·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium channel
    Ä®·ýÅë·Î
  • 11-beta-hydroxylase
    11-º£Å¸-¼ö»êÈ­È¿¼Ò, 11-º£Å¸-È÷µå·Ï½Ç¶óÁ¦
  • 3-beta-hydroxysteroid dehydrogenase
    3-º£Å¸-È÷µå·Ï½Ã½ºÅ×·ÎÀ̵å Å»¼ö¼ÒÈ¿¼Ò
  • Fast channel
    ±Þ¼Ó(ÐááÜ)Åë·Î(÷×ÖØ)
  • O-Nitrophenyl-beta-galactoside => ONPG
    O-´ÏÆ®·ÎÆä´Ò-º£Å¸-°¥¶ôÅä½Ãµå
  • T-type channel
    T-Çü Åë·Î
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • acetylcholine channel
    ¾Æ¼¼Æ¿Äݸ° Åë·Î
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • gamma-delta-beta thalassemia
    °¨¸¶-µ¨Å¸-º£Å¸- ÁöÁßÇØ¼ººóÇ÷
  • hepatocardiac channel
    °£½ÉÀå__ÊÜãýíôϵ).
  • hypoglycemia, beta cell tumor
    ÀúÇ÷´ç(Áõ), º£Å¸¼¼Æ÷Á¾
  • porin channel
    Æ÷¸°Åë·Î
  • pyloric channel
    À¯¹®Åë·Î.
  • potassium
    Ä®·ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium channel
    Ä®·ýÅë·Î
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • cadmium potassium cyanide
    ½Ã¾ÈÈ­Ä«µå¹Ì¿òÄ®·ý.
  • cadmium potassium iodide
    ¿ä¿ÀµåÈ­Ä«µå¹ÅÄ®·ý.
  • caustic potassium
    °¡¼º(Ê´àõ)Ä®·ý.
  • exsiccated potassium alum
    °ÇÁ¶Ä®·ý¸í¹Ý.
  • potassium
    Ä®·ý
  • potassium
    Æ÷Ÿ½·
  • potassium ; kalium
    Æ÷Ÿ½·, Ä®·ý.
  • potassium chloride
    ¿°È­Ä®·ý
  • potassium cyanide broth base
    û»êÄ®·ý¾×ü±âÃʹèÁö
  • potassium determination
    Ä®·ýÃøÁ¤
  • potassium dichromate
    ÁßÅ©·Ò»êÄ®·ý
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium
    Ä®·ý(K)
  • channel
    "ä³Î, Åë·Î(÷×ÖØ)"
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
  • gated channel
    °ü¹® Åë·Î (μڦ÷×ÖØ)
  • ion channel
    À̿ Åë·Î(÷×ÖØ)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • voltage-gated channel
    Àü¾Ð°³Æó(ï³äâËÒøÍ) Åë·Î(÷×ÖØ)
  • beta
    "º£Å¸, (ÔÒ) ¥â"
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta amylase
    º£Å¸ ¾Æ¹Ð·¹À̽º
  • beta bend
    º£Å¸ ±ÁÀ½
  • beta benzyme
    º£Å¸ º¥ÀÚÀÓ
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta carotene
    º£Å¸ Ä«·ÎÅÙ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potassium;kalium
    Æ÷Ÿ½·,Ä®·ý
  • beta
    º£Å¸
  • beta blocker
    º£Å¸Â÷´ÜÁ¦
  • channel
    Åë·Î
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • hepatocardiac channel
    °£½ÉÀ屸
  • lymph channel
    ¸²ÇÁ°ü
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
  • signal channel
    ½ÅÈ£Åë·Î
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BB bad breath; bed bath; beta blockade, beta blocker; BioBreeding [rat]; blanket bath; blood bank; bloo...
MB Bachelor of Medicine [Lat. Medicinae Baccalaureus]; buccal margin; isoenzyme of creatine kinase cont...
MB-CK creatine kinase isoenzyme containing M and B subunits
beta [Greek letter beta] an anomer of a carbohydrate; buffer capacity; carbon separated from a carboxyl by one other carbon i...
BG basal ganglion; basic gastrin; Bender Gestalt [test]; beta-galactosidase; beta-glucuronidase; bicolo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
KATP channel ATP sensitive potassium channel
PCO potassium channel opener
BK channel K channel
KATP ATP dependent potassium
K(ATP) ATP sensitive potassium
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • channel tray ºÐÇÒ º¹À§½Ä ¸ðÇüÀ» Á¦ÀÛÇÒ ¶§ »ç¿ëµÇ´Â ÇÃ¶ó½ºÆ½ ʹÝ. Dilok tray¿Í °°Àº ±â´ÉÀ» ÇÏ´Â °ÍÀÌ´Ù.

    channel-shoulder-pin attachment

    ¾¾ ¿¡½º ÇÇ ºÎ°¡ ÀåÄ¡
    Ä¡°ú ±â°ø½Ç¿¡¼­ Á¦ÀÛÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î °¢Á¾ Àΰø Ä¡°ú
  • beta-aminoisobutyric aciduria ¿äÁß¿¡ º£Å¸-¾Æ¹Ì³ë ¾ÆÀ̼ҴлêÀÌ °úµµ·Î ¹è¼³µÇ´Â °Í. ¾ç¼ºÀÇ À¯Àü¼º ´ë»ç¼º ÀÌ»óÀ¸·Î ÀϾ¸ç ±×¸®°í ƯÁ¤ÇÑ Áúȯ¿¡¼­µµ ³ªÅ¸³­´Ù.

    beta-arrestin

    º£Å¸-¾î·¹½ºÆ¾
  • hetacillin potassium
    Ç쟽Ǹ° Ä®·ý
    Ç쟽Ǹ°ÀÇ Ä®·ý¿°. Ç×±Õ ÀÛ¿ëÀ» °¡Áö°í À־ ¾ÏÇǽǸ°°ú ºñ½ÁÇÏ°Ô »ç¿ëÇÑ´Ù.
  • potassium chloride
    ¿°È­ Ä®·ý
    KCl. Åõ¸íÇÑ ¹é»ö °áÁ¤ ³»Áö ¹é»ö °ú¸³»ó ºÐ¸»·Î¼­ °æ±¸Àû ¶Ç´Â Á¤¸Æ³» ÁÖ»ç·Î Åõ¿©ÇÏ¿© ÀüÇØÁú º¸ÃæÁ¦·Î »ç¿ëµÈ´Ù.
  • potassium hydroxide
    ¼ö½ÅÈ­ Ä®·ý
  • potassium metabolism
    Æ÷Ÿ½Ã¿ò ´ë»ç
  • potassium-sparing agent

    potency

    ÀáÀç´É, ÀáÀç·Â, È¿·Â, ¿ª°¡
  • sodium-potassium exchange resin
    ¼Òµð¿ò-Æ÷Ÿ½· ±³È¯ ¼öÁö
  • calcium channel
    Ä®½· ä³Î
    Ä®½·ÀÌ Åë°úÇÏ´Â µµ°ü.
  • calcium channel blocker
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°, Ä®½· ä³Î Â÷´ÜÁ¦
    µ¿ÀǾî=calcium channel blocking drug. 1. Ä®½·ÀÌ Åë°úÇÏ ´Â µµ°üÀ» ¸·´Â ¾à¹°. 2. Ç× Çù½ÉÁõ Á¦Á¦, Ç×°íÇ÷¾Ð Á¦Á¦, Ç× ºÎÁ¤¸Æ Á¦Á¦·Î »ç¿ëµÇ´Â ¾à¹°·Î½á, µ¿¸ÆÀÇ ÆòȰ±Ù¿¡¼­ Ä®½·ÀÇ À¯ÀÔÀ» Â÷´ÜÇÔÀ¸·Î½á ¸»ÃÊ ¼Òµ¿¸ÆÀ» ÀÌ¿ÏÇØ¼­ ½É±ÙÀÇ »ê¼Ò ¿ä±¸·®À» ÀúÇϽÃŰ´Â ±â´ÉÀ» ÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¾à¹°·Î´Â, vera
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • calcium-channel blocker
    Ä®½· Â÷´ÜÁ¦, Ä®½· Åë·Î Â÷´ÜÁ¦
  • channel block
    Åë·Î Â÷´Ü
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • ion channel
    À̿ Åë·Î
    ¼¼Æ÷¸· µî¿¡ Á¸ÀçÇϸç ÀÚ±ØÀÌ ¿À¸é Åë·Î¸¦ ¿­°í, ´ÝÀ½À¸·Î ÇØ¼­ ÀÌ¿ÂÀÇ ³óµµ¸¦ Á¶ÀýÇØ¼­ ÀÚ±ØÀÇ Àü´Þ¿¡ °ü¿©ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
potassium channel Ion channel selective for potassium ions. There are diverse types with different functions, for example: delayed rectifier channels, M channels, A channels, inward rectifier channels, Ca dependent K channels.
(18 Nov 1997)
androst-5-ene-3 beta,17 beta-diol <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response.
Pharmacological action: anabolic steroids.
Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)-
(12 Dec 1998)
beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings
Registry number: EC 2.4.1.146
Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase
(26 Jun 1999)
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b
Registry number: EC 2.4.1.102
Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t
(26 Jun 1999)
beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase <enzyme> Induced in preneoplastic stage of liver carcinogenesis promoted by orotic acid in rats; adds "bisecting n-acetylglucosaminyl residue in beta 1,4 linkage to the beta-linked mannose of the core of asparagine-linked oligosaccharides
Registry number: EC 2.4.1.144
Synonym: n-acetylglucosaminyltransferase III, udpgnac-glycopeptide beta4-n-acetylglucosaminyl transferase III, udpgnac-magtransferase III, udp-n-acetylglucosamine-beta-d-mannoside beta-1,4-n-acetylglucosaminyltransferase III
(26 Jun 1999)
beta-hydroxy-beta-methylglutaryl-CoA -OOCCH2C(OH)(CH3)CH2COS-CoA;a key intermediate in the synthesis of ketone bodies and of steroids.
Synonym: 3-hydroxy-3-methylglutaryl-CoA.
Beta-hydroxy-beta-methylglutaryl-lyase, an enzyme, found primarily in liver and rumen epithelium that catalyses the formation of acetyl-CoA and acetoacetate from beta-hydroxy-beta-methylglutaryl-CoA; a key step in ketogenesis; a deficiency of this enzyme leads to episodes of severe metabolic acidosis without ketosis.
Beta-hydroxy-beta-methylglutaryl-reductase, an enzyme that catalyses the rate-limiting step of cholesterol biosynthesis, beta-hydroxy-beta-methylglutaryl-CoA + 2NADPH + 2H+ &rarr; mevalonate + 2NADP+ + coenzyme A.
Beta-hydroxy-beta-methylglutaryl-synthase, an enzyme in mitochondria that catalyses the reaction of acetyl-CoA with acetoacetyl-CoA and water to form beta-hydroxy-beta-methylglutaryl-CoA and coenzyme A, a step required for both ketogenesis and steroidogenesis to occur.
(05 Mar 2000)
beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase <enzyme> An enzyme that catalyses the transfer of galactose from udp-galactose to a specific glycoprotein receptor, 2-acetamido-2-deoxy-d-glucosyl-glycopeptide, during glycopeptide synthesis.
Chemical name: UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase
Registry number: EC 2.4.1.38
(12 Dec 1998)
beta, or beta-value <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor.
See: pressure, kinetic pressure, magnetic pressure, second stability.
(09 Oct 1997)
UDP-GalNAc-beta-galactose beta 1,4-N-acetylgalactosaminyltransferase <enzyme> Consider also EC 2.4.1.92
Registry number: EC 2.4.1.-
Synonym: beta-1,4-n-acetylgalactosaminyltransferase, 4-galnactransferase, udp-n-acetylgalactosamine-beta-galactose beta 1,4-n-acetylgalactosaminyltransferase, (1-4)-n-acetyl-beta-d-galactosaminyltransferase, galnact-1
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostate microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 7 alpha-hydroxylase
(26 Jun 1999)
calcium channel <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins.
(12 May 2002)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Large-Conductance Calcium-Activated Potassium Channel beta Subunits - »õâ The regulatory subunits of large-conductance calcium-activated potassium channels.
    Synonyms : Large-Conductance Calcium-Activated Potassium Channels, beta Subunits, MaxiK Channel beta Subunits, Large Conductance Calcium Activated Potassium Channel beta Subunits, Large Conductance Calcium Activated Potassium Channels, beta Subunits
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta
    º£Å¸
  • Phi Beta Kappa
    ÆÄÀÌ.º£Å¸.Ä«ÆÄŬ·´
  • beta
    º£Å¸(±×¸®½º¾î ¾ËÆÄºªÀÇ µÑ° ÀÚ)
  • beta minus
    2·ùÀÇÇÏ;2·ùº¸´Ù Á» ¸øÇÑ
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta rays
    º£Å¸¼±
  • beta rhythm
    º£Å¸¸®µë(¸ÅÃÊ 10ÀÌ»óÀÇ ³úÆÄÀÇ ¹éµ¿)
  • potassium
    Ä®·ý
  • potassium
    Æ÷Ÿ½·;Ä®·ý(±âÈ£ K)
  • potassium bromide
    ºê·ÒÈ­Ä®·ý
  • potassium carbonate
    ź»êÄ®¸®
  • potassium chlorate
    ¿°¼Ò»êÄ®·ý
  • potassium chloride
    ¿°È­Ä®·ý
  • potassium cyanide
    û»êÄ®¸®
  • potassium hydroxide
    ¼ö»êÈ­ Ä®·ý 9
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á